Literature DB >> 8566836

Comparison of effects of calcium carbasalate and aspirin on gastroduodenal mucosal damage in human volunteers.

F E Murray1, N Hudson, J C Atherton, A T Cole, F Scheck, C J Hawkey.   

Abstract

Calcium carbasalate is a therapeutically active salicylate which seems to cause less gastroduodenal mucosal damage than aspirin in laboratory animals. This endoscopist-blinded, randomised, cross over trial aimed to compare acute gastric mucosal damage in 20 healthy volunteers treated with acetyl salicylic acid (ASA) (650 mg three times daily) and effervescent calcium carbasalate (ECC) (826.8 mg three times daily) bioequivalent to 650 mg ASA over a five day period. Endoscopy was performed immediately before treatment and on day 5 of each treatment. Serum salicylate, thromboxane B2, and gastric mucosal prostaglandin E2 (PGE2) concentrations were measured after endoscopy. ECC caused fewer gastric mucosal erosions than ASA. The total number of gastric erosions was 23.8 (16.1) in the ASA treated subjects compared with 9.1 (8.7) in ECC treated subjects (p = 0.004). Differences between ASA and ECC were significant for both the gastric antrum and body, and for both haemorrhagic and non-haemorrhagic erosions. The mean gastric body Lanza score for mucosal damage was lower after ECC than ASA (p = 0.003). The visual analogue score for gastric body damage was lower for ECC (16.9 mm (15.9)) than for ASA (32.7 mm (20.8)), p = 0.008. Serum salicylate concentrations were similar after both preparations (ASA: 66 (23) mg/l, versus ECC: 58 (17) mg/l, NS). Serum thromboxane B2 was similarly reduced using both preparations-97.2 (3.5)% inhibition with ASA, 95.2 (5.5)% inhibition with calcium carbasalate (NS). Suppression of gastric mucosal PGE2 synthesis was similar with both preparations (ASA: 83.4 (17.1)%; ECC 84.3 (12.9)%; NS). It is concluded that ECC causes significantly less gastroduodenal mucosal damage than ASA administered at bioequivalent doses as judged by serum salicylate, serum thromboxane, and mucosal PGE2 values. ECC may therefore be a less harmful alternative treatment to plain ASA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8566836      PMCID: PMC1382971          DOI: 10.1136/gut.38.1.11

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  5 in total

1.  Aspirin and gastrointestinal bleeding. Chromate blood loss studies.

Authors:  R N PIERSON; P R HOLT; R M WATSON; R P KEATING
Journal:  Am J Med       Date:  1961-08       Impact factor: 4.965

2.  [Measurement of gastric transepithelial potential difference. Effect of provocative agents (aspirin, alcohol) and gastric dressings].

Authors:  C Florent; B Flourie; A Pfeiffer; J J Bernier
Journal:  Gastroenterol Clin Biol       Date:  1985

3.  Reduction or prevention of aspirin-induced occult gastrointestinal blood loss in man.

Authors:  J R Leonards; G Levy
Journal:  Clin Pharmacol Ther       Date:  1969 Jul-Aug       Impact factor: 6.875

4.  Separation of the impairment of haemostasis by aspirin from mucosal injury in the human stomach.

Authors:  C J Hawkey; A B Hawthorne; N Hudson; A T Cole; Y R Mahida; T K Daneshmend
Journal:  Clin Sci (Lond)       Date:  1991-10       Impact factor: 6.124

5.  Synthesis of prostaglandin E2, thromboxane B2 and prostaglandin catabolism in gastritis and gastric ulcer.

Authors:  C J Hawkey
Journal:  Gut       Date:  1986-12       Impact factor: 23.059

  5 in total
  6 in total

1.  [1997 gastroenterology update--I].

Authors:  W Fischbach; S S Gro; J Schölmerich; C Ell; P Layer; W E Fleig; H Zirngibl
Journal:  Med Klin (Munich)       Date:  1998-02-15

2.  Stroke: Will cerebral microbleeds influence stroke prevention?

Authors:  Mark O McCarron; Ferghal McVerry
Journal:  Nat Rev Neurol       Date:  2009-11       Impact factor: 42.937

3.  Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans.

Authors:  C J Hawkey; J I Jones; C T Atherton; M M Skelly; J R Bebb; U Fagerholm; B Jonzon; P Karlsson; I T Bjarnason
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

4.  Gastroprotective [6]-Gingerol Aspirinate as a Novel Chemopreventive Prodrug of Aspirin for Colon Cancer.

Authors:  Yingdong Zhu; Fang Wang; Yantao Zhao; Pei Wang; Shengmin Sang
Journal:  Sci Rep       Date:  2017-01-09       Impact factor: 4.379

5.  Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin.

Authors:  J Jaspers Focks; M M Tielemans; L G M van Rossum; T Eikendal; M A Brouwer; J B M J Jansen; R J F Laheij; F W A Verheugt; M G H van Oijen
Journal:  Neth Heart J       Date:  2014-03       Impact factor: 2.380

6.  Buffered aspirin: what is your gut feeling?

Authors:  B C du Pré; L W van Laake
Journal:  Neth Heart J       Date:  2014-03       Impact factor: 2.380

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.